Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2
Phase 4
Recruiting
- Conditions
- prevention covid
- Registration Number
- DRKS00025271
- Lead Sponsor
- niklinik Regensburg Abteilung für Hygiene und Infektiologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 154
Inclusion Criteria
There had been vaccinated 154 HCW of the university clinics of Regensburg an March 15, 2021 with the Astrazeneca vaccine. Everyone who wants to receive the second dose with the vaccine from Biontech is offered the participation in the study.
Exclusion Criteria
First Covid vaccination not with Astrazeneca. contraindication to vaccination with biontech vaccine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood draws before and 4(-6) weeks after the second vaccination with determination of anti-SARS-Cov-2-antiodies in serum by ELISA.<br>A questionnaire will be handed out and collected at date of second blood draw. Side effects of first and second dose will be asked for.
- Secondary Outcome Measures
Name Time Method Comparison of antibody titers with those of vaccinees of another study who received the Biontech vaccine twice